This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Randall, M. E. Articles by Filiaci, V. L. Search for Related Content PubMed Articles by Randall, M. E. Articles by Filiaci, V. L. Related Articles Related Correspondence Social Bookmarking                            What's this?

In Reply

Leo W. Jenkins Cancer Center, Brody School of Medicine at East Carolina University, Greenville, NC

Virgina L. Filiaci

Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY

In Reply:

We appreciate the interest of Drs Ozyar and Genc in Gynecologic Oncology Group study 122.¹ As noted in their letter, 22% of patients in the whole-abdominal irradiation (WAI) arm exhibited their first known recurrence in the liver or an extra-abdominal site compared with 18% of patients in the doxorubicin plus cisplatin (AP) arm. If one looks only at extra-abdominal recurrences and does not consider liver metastases, then the extra-abdominal first failure rates are 19% and 10% for the WAI and AP arms, respectively. There were seven and 13 patients who presented with liver metastases as the site of first recurrence in the WAI and AP groups, respectively.

As Drs Ozyar and Genc know, liver metastasis presumably represents systemic (hematologic) spread of disease. However, the liver is included in the WAI fields. Therefore, we felt it was appropriate to present the distant failure rates both including and excluding liver metastases. It is important to keep in mind that the analysis of failure patterns represents an analysis of the site of first clinically recognized failure. It is not a comprehensive analysis of all sites of failure. Therefore, these failure rates are minimums. The total failure rate for some sites is likely to be higher over the course of the disease. It is also the case that some sites of failure are more clinically obvious than others. Therefore, some uncertainties do exist, and these are discussed in the article.¹

Authors' Disclosures of Potential Conflicts of Interest

The authors indicated no potential conflicts of interest.

REFERENCE

1. Randall ME, Filiaci VL, Muss H, et al: Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 24:36-44, 2006[Abstract/Free Full Text]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Relapse Pattern of GOG 122 Trial Should Be More Informative
  Enis Ozyar and Mine Genc
  JCO 2006 24: 3709-3710 [Full Text]

This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Randall, M. E. Articles by Filiaci, V. L. Search for Related Content PubMed Articles by Randall, M. E. Articles by Filiaci, V. L. Related Articles Related Correspondence Social Bookmarking                            What's this?